Troubles of Two Landmark Cancer Drugs, Celebrex and Iressa, Likely to Shape cancer Prevention, FDA Policy. FDA Mulls Withdrawal of Iressa.
Also in This 8-page Issue: President Bush Nominates EPA Administrator Michael Leavitt for HHS Secretary.
NCI Selects 15 Awardees to Operate the Cancer Information Service.
American Legacy Foundation Says Group is Fighting For Its Survival.
Funding Opportunities Listed.
Trending Stories
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - Kennedy announces massive cuts, centralization at HHS—NCI and FDA hit
Also this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology - In The Headlines: HHS shakeup threatens a legacy of medical breakthroughs
- Jonathan Friedberg tells us how he built a cancer center in an underserved area of New York State
- Ted Kennedy, RFK Jr.’s uncle, shaped the National Cancer Program. Will his nephew follow suit?